FDA approval

Agios insider Krishnan sells $82K in shares via routine RSU tax-withholding event. Retains 16,200 unvested RSUs and recent equity grants signal confidence amid PYRUKYND's 86% revenue growth.

Rosen Law Firm files securities fraud class action against Corcept Therapeutics, alleging misrepresentation of relacorilant drug trial data. Lead plaintiff deadline: April 21, 2026.

Rosen Law Firm urges Inovio Pharmaceuticals investors with losses exceeding $100K to file claims before April 7, 2026 deadline in ongoing securities class action lawsuit.

Glucotrack narrowed net losses to $19.4M in 2025 while advancing implantable glucose monitor toward FDA trials in H2 2026.

BridgeBio reports acoramidis cuts all-cause mortality 44.7% and cardiovascular mortality 49.3% in ATTR-CM patients at Month 54 versus placebo.

$BIOG rallies as FDA approves high-dose Spinraza for spinal muscular atrophy, while litifilimab shows positive Phase 2 lupus results.

Class action filed against $INO alleging executives made false statements about CELLECTRA device manufacturing and INO-3107 regulatory timeline between October 2023 and December 2025.

United Therapeutics stock surges 16.5% after TETON-1 Phase 3 study shows Tyvaso meets primary endpoint in lung fibrosis treatment, with priority FDA review expected by summer 2026.

Teva gains FDA approval for denosumab biosimilar PONLIMSI and achieves dual filing acceptance for omalizumab candidate, bolstering its biosimilars portfolio.

Teva wins FDA approval for PONLIMSI biosimilar and dual regulatory filing acceptance for omalizumab biosimilar, advancing its 'Pivot to Growth' strategy.

Teva gains FDA approval for PONLIMSI denosumab biosimilar and dual regulatory acceptance for omalizumab candidate, advancing biosimilar growth strategy.

Schall Law Firm seeks lead plaintiffs in class action against $QURE for alleged false statements regarding FDA approval timeline and BLA submission misrepresentations.

Rosen Law Firm pursues class action against $CORT for allegedly misrepresenting relacorilant clinical trial data and FDA communications. Lead plaintiff deadline: April 21, 2026.

Novartis' Fabhalta slowed kidney function decline by 49.3% in Phase III trial, with FDA priority review granted for IgA nephropathy treatment.

Rosen Law Firm urges $QURE investors to join securities lawsuit alleging misrepresentation of Pivotal Study design and BLA timeline delays. Lead plaintiff deadline: April 13, 2026.

Alumis reports positive Phase 3 results for envudeucitinib, achieving 68% PASI 90 skin clearance in plaque psoriasis patients, with FDA filing planned for late 2026.

Rosen Law Firm sues Atara Biotherapeutics for allegedly misrepresenting tabelecleucel drug's regulatory prospects and manufacturing capabilities to investors between May 2024 and January 2026. Lead plaintiff deadline set for May 22, 2026.

Corcept Therapeutics stock surged 9% following FDA approval of cancer drug Lifyorli. An analyst upgraded the stock to hold amid concerns about existing Korlym franchise performance.

Monopar reports $13.7M net loss, $140.4M cash reserves funding operations through 2027. Company plans mid-2026 NDA submission for Wilson disease treatment ALXN1840.

Lawsuit filed against Corcept Therapeutics alleging false statements about relacorilant drug trials and FDA communications, covering October 2024-December 2025 investor purchases.